Table 4.
CTCAE grade ≥3 adverse events observed in more than 5% of patients
| Platinum combination therapy (n = 24) | Docetaxel monotherapy (n = 61) | ||||||
|---|---|---|---|---|---|---|---|
| Grade 3 | Grade 4 | Total (%) | Grade 3 | Grade 4 | Total (%) | p value* | |
| Leukocytopenia | 8 | 2 | 10 (41.6) | 30 | 9 | 39 (63.9) | 0.06 |
| Neutropenia | 8 | 6 | 14 (58.3) | 16 | 28 | 44 (72.1) | 0.08 |
| Anemia | 3 | 0 | 3 (12.5) | 2 | 0 | 2 (3.3) | 0.12 |
| Febrile neutropenia | 2 | 0 | 2 (8.3) | 6 | 0 | 6 (9.8) | 0.82 |
| Anorexia | 1 | 0 | 1 (4.2) | 5 | 0 | 5 (8.2) | 0.49 |
| Infection | 1 | 0 | 1 (4.2) | 3 | 0 | 3 (4.9) | 0.88 |
Abbreviations: CTCAE, Common Terminology Criteria for Adverse Events version 3.0.
*Fisher’s exact test.